FCMI
JNCE

Foresite Capital Management II’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Foresite Capital Management II’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-119,912
Closed -$1.87M – 13
2017
Q3 		$1.87M Hold
119,912
– – 0.76% 8
2017
Q2 		$1.68M Hold
119,912
– – 0.77% 8
2017
Q1 		$2.64M Buy
+119,912
New +$2.54M 1.13% 8

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Foresite Capital Management II's JNCE Position: Q4 2017 in Review

Foresite Capital Management II sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2017, closing a stake of 119,912 shares — an estimated $1.87M sold.

Foresite Capital Management II first reported a position in JNCE in Q1 2017 and held it in 3 quarters. The position peaked at $2.64M in Q1 2017. 83 funds tracked by Wall St. Rank hold JNCE as of Q4 2017.

  • Foresite Capital Management II reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Foresite Capital Management II sold 119,912 Jounce Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $1.87M.
  • Foresite Capital Management II first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Foresite Capital Management II's Jounce Therapeutics, Inc. Common Stock position peaked at $2.64M in Q1 2017.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Foresite Capital Management II's 13F filing for Q4 2017, filed 13 Feb 2018.